mRNA Cancer Vaccine Clears Late-Stage Melanoma Trial
“A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.”
The claim is now supported by direct evidence. On August 19, 2026, Merck and Moderna announced that the Phase 3 INTerpath-001 trial of their personalized mRNA cancer vaccine, intismeran, met both its primary goal of reducing melanoma recurrence and its secondary goal of preventing cancer spread. The trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma, and STAT...